Indaptus (INDP) director receives 25,000 shares and 25,000 options

Rhea-AI Filing Summary

Indaptus Therapeutics director Avraham Ben-Tzvi reported new equity awards. On January 20, 2026, he received 25,000 shares of restricted common stock as compensation under a consulting agreement, and these shares vested in full immediately upon grant. Following this award, he beneficially owns 25,100 shares of Indaptus common stock, including 100 shares held in a Roth IRA.

Separately, on December 23, 2025, he was granted options to purchase 25,000 shares of Indaptus common stock under the company’s non-employee director compensation program. These stock options vest over three years in equal quarterly installments, so long as he continues to serve on the board through each vesting date.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Ben-Tzvi Avraham

(Last) (First) (Middle)

44 ZAYT SHEMEN ST., FLAT 4

(Street)

EFRAT L3 9045544

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Indaptus Therapeutics, Inc. [ INDP ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

3. Date of Earliest Transaction (Month/Day/Year)
12/23/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	01/20/2026		A		25,000	A	$0.00(1)	25,100(2)	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Option to Buy Common Stock	$1.95	12/23/2025		A		25,000		(3)	12/23/2035	Common Stock	25,000	$0.00(3)	25,000	D

Explanation of Responses:

1. The Reporting Person acquired 25,000 shares of restricted common stock of the Issuer pursuant to a consulting agreement dated January 20, 2026, which shares vested 100% upon grant.

2. Includes 100 shares of common stock of the Issuer held in a Roth IRA.

3. The Reporting Person acquired options to purchase 25,000 shares of common stock pursuant to the Issuer's non-employee director compensation program. The stock options vest over three years commencing from the date of grant in equal quarterly installments subject to continued service on the Board through each vesting date.

	/s/ Avraham Ben-Tzvi	01/22/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What insider transactions did INDP director Avraham Ben-Tzvi report?

He reported receiving 25,000 shares of restricted common stock on January 20, 2026, and options to buy 25,000 shares of common stock granted on December 23, 2025.

How many Indaptus Therapeutics (INDP) shares does Avraham Ben-Tzvi now beneficially own?

After the reported stock grant, he beneficially owns 25,100 shares of Indaptus common stock, which includes 100 shares held in a Roth IRA.

What are the terms of the restricted stock granted to the INDP director?

The director acquired 25,000 restricted shares of Indaptus common stock under a consulting agreement dated January 20, 2026, and these shares vested 100% upon grant.

What are the vesting terms of the options granted to the Indaptus director?

The options to purchase 25,000 shares of Indaptus common stock vest over three years in equal quarterly installments, starting from the December 23, 2025 grant date, subject to continued board service at each vesting date.

Are the equity awards to the INDP director direct or indirect holdings?

Both the restricted stock and the options are reported as direct holdings. The 25,100 common shares beneficially owned include 100 shares held in a Roth IRA.

Under what programs or agreements were the INDP equity awards made?

The 25,000 restricted shares were granted under a consulting agreement dated January 20, 2026, and the 25,000 stock options were granted under Indaptus’s non-employee director compensation program.